中华核医学与分子影像杂志
中華覈醫學與分子影像雜誌
중화핵의학여분자영상잡지
Chinese Journal of Nuclear Medicine and Molecular Imaging
2013年
4期
248-251
,共4页
邹雷%罗开元%马振桓%李波%李晓刚%许建彪%陆炯
鄒雷%囉開元%馬振桓%李波%李曉剛%許建彪%陸炯
추뢰%라개원%마진환%리파%리효강%허건표%륙형
胃肿瘤%近距离放射疗法%碘放射性同位素
胃腫瘤%近距離放射療法%碘放射性同位素
위종류%근거리방사요법%전방사성동위소
Stomach neoplasms%Brachytherapy%Iodine radioisotopes
目的 探讨125I粒子组织间植人治疗胃癌的有效性及该方法能否提高患者生存率.方法 选取同时期Ⅱ、Ⅲ期胃癌患者76例,按单纯随机分为根治性手术组(34例,仅行根治性手术,D2、D3术式)和根治性手术+125I粒子组(42例,行根治性手术+125I粒子治疗).治疗效果分CR(治疗后肿瘤完全消失达1个月以上)、PR(肿瘤较治疗前缩小50％以上至少1个月)、NC和PD,CR+PR为治疗有效,据此计算有效率.随访并计算患者生存率及并发症发生情况.率的比较采用x2检验.结果 根治性手术组总有效率50.00％ (17/34),根治性手术+125I粒子组总有效率为73.81％(31/42),2组差异有统计学意义(x2=4.578,P＜0.05).根治性手术+1251粒子组3年和5年生存率分别为61.90％(26/42)和42.86％ (18/42),均高于根治性手术组[11.76(4/34)和0(0/34)；x2=19.771和19.094,均P＜0.001].2组毒性和不良反应均较少.结论 根治性手术+125I粒子植入治疗Ⅱ、Ⅲ期胃癌较单纯根治性手术更有效,能进一步提高远期生存率,不良反应少.
目的 探討125I粒子組織間植人治療胃癌的有效性及該方法能否提高患者生存率.方法 選取同時期Ⅱ、Ⅲ期胃癌患者76例,按單純隨機分為根治性手術組(34例,僅行根治性手術,D2、D3術式)和根治性手術+125I粒子組(42例,行根治性手術+125I粒子治療).治療效果分CR(治療後腫瘤完全消失達1箇月以上)、PR(腫瘤較治療前縮小50％以上至少1箇月)、NC和PD,CR+PR為治療有效,據此計算有效率.隨訪併計算患者生存率及併髮癥髮生情況.率的比較採用x2檢驗.結果 根治性手術組總有效率50.00％ (17/34),根治性手術+125I粒子組總有效率為73.81％(31/42),2組差異有統計學意義(x2=4.578,P＜0.05).根治性手術+1251粒子組3年和5年生存率分彆為61.90％(26/42)和42.86％ (18/42),均高于根治性手術組[11.76(4/34)和0(0/34)；x2=19.771和19.094,均P＜0.001].2組毒性和不良反應均較少.結論 根治性手術+125I粒子植入治療Ⅱ、Ⅲ期胃癌較單純根治性手術更有效,能進一步提高遠期生存率,不良反應少.
목적 탐토125I입자조직간식인치료위암적유효성급해방법능부제고환자생존솔.방법 선취동시기Ⅱ、Ⅲ기위암환자76례,안단순수궤분위근치성수술조(34례,부행근치성수술,D2、D3술식)화근치성수술+125I입자조(42례,행근치성수술+125I입자치료).치료효과분CR(치료후종류완전소실체1개월이상)、PR(종류교치료전축소50％이상지소1개월)、NC화PD,CR+PR위치료유효,거차계산유효솔.수방병계산환자생존솔급병발증발생정황.솔적비교채용x2검험.결과 근치성수술조총유효솔50.00％ (17/34),근치성수술+125I입자조총유효솔위73.81％(31/42),2조차이유통계학의의(x2=4.578,P＜0.05).근치성수술+1251입자조3년화5년생존솔분별위61.90％(26/42)화42.86％ (18/42),균고우근치성수술조[11.76(4/34)화0(0/34)；x2=19.771화19.094,균P＜0.001].2조독성화불량반응균교소.결론 근치성수술+125I입자식입치료Ⅱ、Ⅲ기위암교단순근치성수술경유효,능진일보제고원기생존솔,불량반응소.
Objective To explore the effectiveness of 125I seed implantation for gastric cancer and to determine whether the therapy could increase the survival rate.Methods Seventy-six gastric cancer patients in stage Ⅱ or Ⅲ were involved and randomly divided into treatment group (n =42) and control group (n =34)by simple random sampling method.The patients in the control group underwent D2 or D3 surgery and the patients in treatment group underwent D2 or D3 surgery plus interstitial implantation of 125I seeds.All patients signed the informed consents.Treatment results were evaluated as CR,PR,NC and PD.CR and PR were considered as effective and the effective rate was calculated.All patients were followed up and the three-or five-year survival rate was calculated,the complications were examined.x2 test was used to compare the significant difference between the two groups.Results The total effective rate in control group was 50.00％ (17/34),lower than that of treatment group (73.81％,31/42; x2 =4.578,P＜0.05).In the treatment group,the three-year and five-year survival rates were 61.90％(26/42) and 42.86％(18/42) respectively,and the corresponding rates in the control group were 11.76％(4/34) and 0(0/34) respectively (x2=19.771,19.094,both P＜0.001).Both of the two groups had few severe side effects.Conclusion Radical surgery plus 1~Iseed implantation is effective and safe for the treatment of stage Ⅱ or Ⅲ gastric cancer and can further improvelong-term survival.
